T-Select H-2K^b OVA Tetramer-SIINFEKL-PE

1. Teramoto K et al. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy. Cancer Res. 63, 7920-5 (2003)(PMID:14633722)

1. Li W et al. Immunostimulating properties of intragastrically administered Acetobacter-derived soluble branched (1,4)-beta-D-glucans decrease murine susceptibility to Listeria monocytogenes. Infect  Immun. 72, 7005-11 (2004)(PMID:15557623)

1. Yajima T et al. A novel role of IL-15 in early activation of memory CD8+ CTL after reinfection. J Immunol. 174, 3590-7 (2005)(PMID:15749896)

1. Nabekura T et al. Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap. Mol Ther. 13, 301-9 (2006)(PMID:16311073)

1. Yajima T et al. IL-15 regulates CD8+ T cell contraction during primary infection. J Immunol. 176, 507-15 (2006)(PMID:16365444)

1. Wakita D et al. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int Immunol. 18, 425-34 (2006)(PMID:16415100)

1. Yokouchi H et al. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer. Cancer Sci. 97, 148-54 (2006)(PMID:16441426)

1. Chamoto K et al. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Cancer Res. 66, 1809-17 (2006)(PMID:16452242)

1. Saito K et al. Impaired protection against Mycobacterium bovis bacillus Calmette-Guerin infection in IL-15-deficient mice. J Immunol. 176, 2496-504 (2006)(PMID:16456010)

1. Taneichi M et al. Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol. 177, 2324-30 (2006)(PMID:16887993)

1. Zhang Y et al. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Int Immunol. 19, 151-61 (2007)(PMID:17189593)

1. Li W et al. Tyk2 signaling in host environment plays an important role in contraction of antigen-specific CD8+ T cells following a microbial infection. J Immunol. 178, 4482-8 (2007)(PMID:17372006)

1. Sugiyama T et al. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7. Int Immunol. 20, 1-9 (2008)(PMID:17981792)

1. Kumar H et al. Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol. 180, 683-7 (2008)(PMID:18178804)

1. Wakabayashi A et al. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin. J. Immunol. 180, 4000-10 (2008)(PMID:18322209)

1. Miyakoda M et al. Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection. J Immunol. 181, 1420-8 (2008)(PMID:18606696)

1. Kijima M et al. Jagged1 suppresses collagen-induced arthritis by indirectly providing a negative signal in CD8+ T cells. J Immunol. 182,  3566-72 (2009)(PMID:19265135)

1. Tang C et al. IL-15 protects antigen-specific CD8+ T cell contraction after Mycobacterium bovis bacillus Calmette-Guérin infection. J Leukoc Biol. 86, 187-94 (2009)(PMID:19389797)

1. Senju S et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cell 27, 1021-31 (2009)(PMID:19415766)

1. Asano J et al. Nucleotide oligomerization binding domain-like receptor signaling enhances dendritic cell-mediated cross-priming in vivo. J Immunol. 184, 736-45 (2010)(PMID:20008287)

1. Takeshima T et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70, 2697-706 (2010)(PMID:20215523)

1. Kuwada E et al. Insoluble fraction of tumor cell homogenate is a useful material for eliciting cytotoxic T lymphocytes: a unique method for protein solubilization. Anticancer Res. 31, 881-91 (2011)(PMID:21498709)

1. Yanai H et al. Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs). PNAS. 108, 11542-7 (2011)(PMID:21709231)

1. Kurachi S et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med. 208, 1605-20 (2011)(PMID:21788406)

1. Fukaya T et al. Conditional ablation of CD205+ conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo. PNAS. 109, 11288-93 (2012)(PMID:22736794)

1. Shimizu K et al. Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol. 190, 5609-5619 (2013)(PMID:23630347)

1. Yamada H et al. Positive selection of self-antigen-specific CD8+ T cells by hematopoietic cells. Eur J Immunol 43, 2033-42 (2013)(PMID:23636825)

1. Yamazaki C et al. Critical roles of a dendritic cell subset expressing a chemokine receptor, XCR1. J Immunol. 190, 6071-6082 (2013)(PMID:23670193)

1. Kimura K et al. CD8+ T cells specific for a malaria cytoplasmic antigen form clusters around infected hepatocytes and are protective at the liver stage of infection. Infect Immun. 81, 3825-34 (2013)(PMID:23897612)

1. Kobiyama K et al. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. PNAS 111, 3086-91 (2014)(PMID:24516163)

1. Tsukamoto H et al. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res. 1, 64-76 (2013)(PMID:24777249)

1. Ito M et al. Combinatorial contextualization of peptidic epitopes for enhanced cellular immunity. PLoS One 9, e110425 (2014)(PMID:25343355)

1. Sawada Y et al. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol. 46, 28-36 (2015)(PMID:25354479)

1. Toyota H et al. Vaccination with OVA-bound nanoparticles encapsulating IL-7 inhibits the growth of OVA-expressing E.G7 tumor cells in vivo. Oncol Rep. 33, 292-6 (2015)(PMID:25394516)

1. Eikawa S et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. PNAS. 112, 1809-14 (2015)(PMID:25624476)

1. Fu C et al. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. PNAS. 112, 2823-8 (2015)(PMID:25730849)

1. Hanson MC et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. J Clin Invest. 125, 2532-46 (2015)(PMID:25938786)

1. Sasaki K et al. Thymoproteasomes produce unique peptide motifs for positive selection of CD8(+) T cells. Nat Commun. 6, 7484 (2015)(PMID:26099460)

1. Ito D et al. mTOR Complex Signaling through the SEMA4A-Plexin B2 Axis Is Required for Optimal Activation and Differentiation of CD8+ T Cells. J Immunol. 195, 934-43 (2015)(PMID:26116500)

1. Seregin SS et al. Dissecting CD8+ NKT Cell Responses to Listeria Infection Reveals a Component of Innate Resistance. J Immunol 195, 1112-20 (2015)(PMID:26116513)

1. Takada K et al. TCR affinity for thymoproteasome-dependent positively selecting peptides conditions antigen responsiveness in CD8(+) T cells. Nat Immunol. 16, 1069-76 (2015)(PMID:26301566)

1. Pearce VQ et al. PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes. J Immunol 195, 3206-17 (2015)(PMID:26311905)

1. Kamimura D et al. Strong TCR-mediated signals suppress integrated stress responses induced by KDELR1 deficiency in naive T cells. Int Immunol. 28, 117-26 (2016)(PMID:26489882)

1. Rapaport AS et al. The Inhibitory Receptor NKG2A Sustains Virus-Specific CD8⁺ T Cells in Response to a Lethal Poxvirus Infection. Immunity 43, 1112-24 (2015)(PMID:26680205)

1. Uto T et al. Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity. Nat Commun. 7, 11273 (2016)(PMID:27068492)

1. Takeda Y et al. Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8(+) T cells during vaccine immunotherapy. J Exp Clin Canc Res. 35,143 (2016)(PMID:27619885)

1. Llopiz D et al. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Oncotarget 8, 2659-2671 (2017)(PMID:27926522)

1. Ito M et al. Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cells. PLoS One. 12, e0188934 (2017)(PMID:29190754)

1. Takahashi H et al. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides. Front Immunol. 9, 783 (2018)(PMID:29720976)

1. Takeda Y et al. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci. 109, 2119-2129 (2018)(PMID:29791768)

1. Wakabayashi A et al. HMGB1 released from intestinal epithelia damaged by cholera toxin adjuvant contributes to activation of mucosal dendritic cells and induction of intestinal cytotoxic T lymphocytes and IgA. Cell Death Dis. 9, 631 (2018)(PMID:29795370)

1. Piccirillo AR et al. Histone acetyltransferase CBP is critical for conventional effector and memory T-cell differentiation in mice. J Biol Chem. 294, 2397-2406 (2019) (PMID:30573679)

1. Xu Y et al. A versatile supramolecular nanoadjuvant that activates NF-κB for cancer immunotherapy. Theranostics. 9, 3388-3397 (2019)(PMID:31244959)

1. Yue Yin et al. Simultaneous delivery of DNA vaccine and hydrophobic adjuvant using reducible polyethylenimine-functionalized graphene oxide for activation of dendritic cells

1. Xu J et al. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 15, 1043-1052 (2020)(PMID:33139933)

Flow Cytometry

1. Kos S et al. Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma. PLoS One. 14, e0217762 (2019)(PMID:31150505)
2. Nguyen QT et al. Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine. Front Immunol. 10, 1604 (2019)(PMID:31354739)
3. Poupiot J et al. Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle. Mol Ther Methods Clin Dev. 15, 83-100 (2019)(PMID:31649958)
4. Lv M et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 30, 966-979 (2020)(PMID:32839553)